US Regulatory Pathway The Breast Cancer Locator is investigational in the United States and is being studied in a pivotal trial, indicating a clear near-to-market expansion path once clearance is achieved; prioritize engaging trial sites, breast surgery departments, and KOLs to secure early access programs and long-term adoption.

Europe Market Ready Europe already has commercial availability; leverage EU market presence to generate case studies, reimbursement conversations, and distributor partnerships, while preparing for U.S. marketing clearance with aligned messaging and clinical data.

Clinical Access Focus Target cancer centers, breast surgery units, radiology imaging teams, and perioperative staff to position the Breast Cancer Locator as a workflow-enhancing tool that can improve precision in tumor localization and surgical planning.

3D Printing Partners Product relies on patient imaging data and state-of-the-art 3D printing; explore partnerships with imaging providers, hospital procurement teams, and 3D printing vendors to speed adoption, integrate into surgical workflows, and expand channel reach.

Strategic Funding Recent Series A2 financing signals investor interest in precision medtech; pursue co-development, strategic investment, or distribution partnerships with interested investors and corporate partners while highlighting Europe-US expansion potential.